Will AbbVie now emerge as the next megamerger target?

AbbVie CEO Richard Gonzalez

Now that AbbVie ($ABBV) has hammered out its $55 billion takeover deal for Shire ($SHPG), analysts are looking for the next big biopharma tax inversion deal. And UBS analyst Guillaume van Renterghem tells Bloomberg that Switzerland's Actelion ($ATLN)--a longtime favorite among takeover targets--is a good possibility as the industry consolidates into low-tax domiciles. The news service also raised the prospect of a takeover of the generic drug company Perrigo. But bigger than both would be AbbVie itself, which could emerge as a megamerger target once it completes its Shire buyout and moves its tax residency. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.